HN2010002157A - Antagonistas de la trayectoria hedgehog de ftalazina disustituida - Google Patents

Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Info

Publication number
HN2010002157A
HN2010002157A HN2010002157A HN2010002157A HN2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A HN 2010002157 A HN2010002157 A HN 2010002157A
Authority
HN
Honduras
Prior art keywords
hedgehog
antagonists
ftalazina
disttituted
history
Prior art date
Application number
HN2010002157A
Other languages
English (en)
Spanish (es)
Inventor
Philip Arthur Hipsikind
Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2010002157A publication Critical patent/HN2010002157A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HN2010002157A 2008-04-29 2010-10-21 Antagonistas de la trayectoria hedgehog de ftalazina disustituida HN2010002157A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29

Publications (1)

Publication Number Publication Date
HN2010002157A true HN2010002157A (es) 2014-09-08

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010002157A HN2010002157A (es) 2008-04-29 2010-10-21 Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Country Status (22)

Country Link
US (1) US7981892B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2294061A2 (US20070167479A1-20070719-C00034.png)
JP (1) JP5442717B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR101260116B1 (US20070167479A1-20070719-C00034.png)
CN (1) CN102066353B (US20070167479A1-20070719-C00034.png)
AU (1) AU2009241561B2 (US20070167479A1-20070719-C00034.png)
BR (1) BRPI0911618A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2723042A1 (US20070167479A1-20070719-C00034.png)
CO (1) CO6300945A2 (US20070167479A1-20070719-C00034.png)
CR (1) CR11741A (US20070167479A1-20070719-C00034.png)
DO (1) DOP2010000302A (US20070167479A1-20070719-C00034.png)
EA (1) EA201071248A1 (US20070167479A1-20070719-C00034.png)
EC (1) ECSP10010577A (US20070167479A1-20070719-C00034.png)
HN (1) HN2010002157A (US20070167479A1-20070719-C00034.png)
IL (1) IL208211A0 (US20070167479A1-20070719-C00034.png)
MA (1) MA32349B1 (US20070167479A1-20070719-C00034.png)
MX (1) MX2010011948A (US20070167479A1-20070719-C00034.png)
MY (1) MY159491A (US20070167479A1-20070719-C00034.png)
NZ (1) NZ588001A (US20070167479A1-20070719-C00034.png)
UA (1) UA102250C2 (US20070167479A1-20070719-C00034.png)
WO (1) WO2009134574A2 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201006695B (US20070167479A1-20070719-C00034.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
DK2364185T3 (da) * 2008-11-03 2013-06-03 Lilly Co Eli Disubstituerede phthalazin-hedgehog-pathway-antagonister
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
CN102216292B (zh) * 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
RU2012125152A (ru) * 2009-11-18 2013-12-27 Новартис Аг Способы и композиции, предназначенные для лечения солидных опухолей и других злокачественных новообразований
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
EP2895474B1 (en) 2012-09-17 2019-12-11 Duke University Smoothened receptor modulators and methods of use thereof
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
EP0876366B1 (en) 1996-01-15 2001-07-25 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
EP1067939B1 (en) 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60016402T2 (de) 1999-06-08 2005-10-27 Lorantis Ltd. Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
AU2005260102A1 (en) 2004-05-08 2006-01-12 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
PL1789390T3 (pl) 2004-09-02 2012-04-30 Genentech Inc Pirydylowe inhibitory szlaku sygnałowego hedgehog
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
NZ588001A (en) 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
DK2364185T3 (da) 2008-11-03 2013-06-03 Lilly Co Eli Disubstituerede phthalazin-hedgehog-pathway-antagonister
CN102216292B (zh) 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
EA201071248A1 (ru) 2011-06-30
ECSP10010577A (es) 2010-11-30
ZA201006695B (en) 2012-09-26
NZ588001A (en) 2012-06-29
WO2009134574A2 (en) 2009-11-05
AU2009241561A1 (en) 2009-11-05
IL208211A0 (en) 2010-12-30
JP5442717B2 (ja) 2014-03-12
MA32349B1 (fr) 2011-06-01
CN102066353B (zh) 2013-12-11
EP2294061A2 (en) 2011-03-16
JP2011527666A (ja) 2011-11-04
CN102066353A (zh) 2011-05-18
MX2010011948A (es) 2010-12-14
KR101260116B1 (ko) 2013-05-02
US20110046143A1 (en) 2011-02-24
BRPI0911618A2 (pt) 2019-09-24
AU2009241561B2 (en) 2013-05-16
CO6300945A2 (es) 2011-07-21
WO2009134574A3 (en) 2014-09-04
KR20100126580A (ko) 2010-12-01
CA2723042A1 (en) 2009-11-05
DOP2010000302A (es) 2010-11-15
MY159491A (en) 2017-01-13
US7981892B2 (en) 2011-07-19
UA102250C2 (ru) 2013-06-25
CR11741A (es) 2011-01-05

Similar Documents

Publication Publication Date Title
HN2010002157A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
ECSP19026680A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
UY29186A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
CY1120054T1 (el) Ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νευρολογικων και ψυχολογικων διαταραχων
CR20120051A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteína
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
ECSP10010585A (es) Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso
AR079889A1 (es) Antagonistas de wnt y metodos de tratamiento y deteccion
UY34539A (es) Heteroarilos y usos de los mismos
CR20120620A (es) Nuevas formas de rifaximina y usos de las mismas
UY30835A1 (es) 8-alquinilxantinas y derivados
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
CR11438S (es) Sistema de iluminacion
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
ECSP11011482A (es) Piperidinas sustituidas
ECSP067039A (es) Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UY29718A1 (es) Un método para desecar y/o desfoliar cultivos resistentes a glifosato
CL2009000367A1 (es) Compuestos derivados de tiofen-amidas, inhibidores de los factores de la coagulacion xa y trombina; procedimiento de preparacion; composicion farmaceutica; y uso en trastornos cardiovasculares, enfermedades tromboembolicas o restenosis.
CO6470822A2 (es) Piperidinas susituidas
ECSP088147A (es) Moduladores del receptor de la cianopirrol-sulfonamida progesterona y los usos de los mismos